Overview of Nova Eye Medical's Record USA Sales

Nova Eye Medical Limited (ASX: $EYE) has achieved record USA sales for February 2024, reaching US$0.99 million, marking a 20% increase from January 2024. The company's sales revenue for the USA in the 2 months ended 29 February 2024 was US$1.82 million, reflecting a remarkable 65% growth compared with the prior comparative period (PCP).

Executive Commentary on Sales Performance

The strong performance in the USA during this period was primarily driven by the positive reception and adoption of our iTrack™ Advance by US surgeons since its launch in May 2023. We have received exceptional feedback on the product's performance from both new and existing customers. The sales growth in February 2024, which was 20% higher than January 2024 and 11% higher than the previous record month in October 2023, demonstrates the resilience and potential of our glaucoma surgical devices in the market.

Summary of Nova Eye Medical's Sales Announcement

Nova Eye Medical Limited (ASX: $EYE) has reported a significant surge in USA sales, with a record US$0.99 million achieved in February 2024, representing a 20% increase from January 2024. The company's sales revenue for the USA in the 2 months ended 29 February 2024 was US$1.82 million, reflecting an impressive 65% growth compared with the prior comparative period (PCP). The strong performance was attributed to the successful uptake of iTrack™ Advance by US surgeons since its launch in May 2023, with positive feedback contributing to the sales growth. The company also noted that sales outside the USA were in line with the prior comparative period. Looking ahead, Nova Eye Medical remains focused on leveraging its innovative glaucoma surgical devices to drive sustained growth and meet the evolving needs of eye surgeons globally.